Open Veils
AboutBrowse

Open Veils · Answer

Australia and Alpha-1 antitrypsin deficiency

Australia carries a significant undiagnosed AATD burden — TSANZ estimates over 30,000 affected individuals across Australia and New Zealand, yet fewer than 10% have ever been identified. Augmentation therapy, the primary disease-modifying intervention, has severely limited availability in Australia, leaving most patients managed symptomatically. The condition is routinely misclassified as COPD, asthma, or chronic bronchitis, delaying genetic investigation by years or decades. This diagnostic gap represents a structural failure, not a knowledge gap — the testing infrastructure exists but the screening culture does not.

Evidence

  • The Royal College of Pathologists of Australasia (RCPA) documents that over 100 genetic variants of SERPINA1 exist, of which PIZ and PIS are the most common pathogenic alleles.
  • Respiratory Medicine Today (April 2026) confirms the clinical signature: panlobular, basal-predominant emphysema, disproportionate to smoking history, with augmentation therapy — intravenous purified AAT protein — holding only limited availability in Australia.
  • The Alpha-1 Australia Association (AAA) and the Alpha-1 Organisation of Australia (A1OA) both flag that Australians are predominantly reaching diagnosis only after a COPD or emphysema label is already entrenched — by which point irreversible alveolar destruction has often occurred.
  • Crucially, the RCPA notes that acute-phase responses elevate AAT levels and can mask deficiency — meaning a standard immunoassay in an unwell patient can return a falsely normal result.
  • Genotyping should proceed regardless of serum level when clinical suspicion is high.

Ask your own question

Related questions

Share this answer